Log In
BCIQ
Print this Print this
 

YH25448

  Manage Alerts
Collapse Summary General Information
Company Yuhan Corp.
DescriptionThird-generation tyrosine kinase inhibitor (TKI) targeting the initial EGFR-activating mutation and the T790M EGFR resistance mutation
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$126.0M

$6.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/28/2016

$126.0M

$6.0M

$120.0M

Get a free BioCentury trial today